drugset / Trial / NCT06985472
Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, prospective cohort study. The main purpose of study is to evaluate the efficacy and safety of Orelabrutinib combined with Zuberitamab in the initial treatment of MZL Main efficacy indicators Complete response rate (CR) at the end of combination therapy.
Timeline
- Start
- 2024-11-13
- Primary completion
- 2025-12-01
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | 150 mg | Oral |
| Subject | Zuberitamab | Monoclonal antibody | 375 mg/m2 | Intravenous |